- Home
- BNRG vs ICU Comparison
BNRG vs ICU Comparison
Compare BNRG & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- ICU
- Stock Information
- Founded
- BNRG 2012
- ICU 2018
- Country
- BNRG Israel
- ICU United States
- Employees
- BNRG N/A
- ICU N/A
- Industry
- BNRG
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- BNRG
- ICU Health Care
- Exchange
- BNRG Nasdaq
- ICU Nasdaq
- Market Cap
- BNRG 10.0M
- ICU 10.4M
- IPO Year
- BNRG 2022
- ICU N/A
- Fundamental
- Price
- BNRG $1.31
- ICU $1.26
- Analyst Decision
- BNRG
- ICU
- Analyst Count
- BNRG 0
- ICU 0
- Target Price
- BNRG N/A
- ICU N/A
- AVG Volume (30 Days)
- BNRG 36.5K
- ICU 199.2K
- Earning Date
- BNRG 03-04-2025
- ICU 05-13-2025
- Dividend Yield
- BNRG N/A
- ICU N/A
- EPS Growth
- BNRG N/A
- ICU N/A
- EPS
- BNRG N/A
- ICU N/A
- Revenue
- BNRG N/A
- ICU $135,000.00
- Revenue This Year
- BNRG N/A
- ICU $648.15
- Revenue Next Year
- BNRG N/A
- ICU $100.00
- P/E Ratio
- BNRG N/A
- ICU N/A
- Revenue Growth
- BNRG N/A
- ICU N/A
- 52 Week Low
- BNRG $0.60
- ICU $1.11
- 52 Week High
- BNRG $3.27
- ICU $14.98
- Technical
- Relative Strength Index (RSI)
- BNRG 50.12
- ICU 35.62
- Support Level
- BNRG $1.31
- ICU $1.15
- Resistance Level
- BNRG $1.42
- ICU $1.35
- Average True Range (ATR)
- BNRG 0.13
- ICU 0.12
- MACD
- BNRG 0.00
- ICU 0.01
- Stochastic Oscillator
- BNRG 62.50
- ICU 41.67
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.